Latest News

Study finds systemic AD treatment relieves depressive symptoms along with skin symptoms


 

FROM ISAD 2022


Dr. Joseph pointed out that taking the deep dive also involves being prepared for what comes up. “Once you’ve established there’s a mental health issue, what do you do then?” she said. “If you are a dermatologist, is that in your wheelhouse to address? There’s the education and connection piece for the physician, creating networks where – if you identify a patient who has an issue – who is a person I can send them to? We have these types of connections with infectious disease or with ophthalmologists if there are ocular symptoms, but mental health is one area where there may not be as much support for dermatologists.”

She noted that though all doctors learn how to screen for depression, “there’s the formulaic, yes/no answers, and then there’s the nuanced history-taking, creating a safe space, where the patient is going to answer you fulsomely ... and feel heard. Many of us know how to do that. The question is time.”

Dr. Ivert had no disclosures connected to this study. Dr. Joseph had no disclosures.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Roflumilast foam effectively eases seborrheic dermatitis
MDedge Family Medicine
Tralokinumab earns EU recommendation to expand age range for atopic dermatitis to include adolescents
MDedge Family Medicine
Early emollient use reduces dermatitis in at-risk infants
MDedge Family Medicine
Many factors linked with higher, lower risk for hand eczema
MDedge Family Medicine
FDA approves dupilumab for treatment of prurigo nodularis
MDedge Family Medicine
Study identifies skin biomarkers that predict newborn eczema risk
MDedge Family Medicine
BREEZE-AD-PEDS: First data for baricitinib in childhood eczema reported
MDedge Family Medicine
52-week data show lebrikizumab atopic dermatitis effects maintained
MDedge Family Medicine
Dupilumab study outlines benefits, safety profile in infants, preschoolers with atopic dermatitis
MDedge Family Medicine
Dermatologists fear effects of Dobbs decision for patients on isotretinoin, methotrexate
MDedge Family Medicine